|  | | **Peritoneal Cytology** | |  |
| --- | --- | --- | --- | --- |
| **Characteristic** | **Overall**, N = 7331 | **Negtive**, N = 6741 | **Malignant**, N = 591 | **P value**2 |
| **Year of Diagnosis** |  |  |  | 0.8283 |
| 2010-2011 | 216 (29.5%) | 198 (29.4%) | 18 (30.5%) |  |
| 2012-2013 | 217 (29.6%) | 198 (29.4%) | 19 (32.2%) |  |
| 2014-2016 | 300 (40.9%) | 278 (41.2%) | 22 (37.3%) |  |
| **Age (years)** | 55.8 (12.4) | 55.7 (12.3) | 56.6 (13.5) | 0.6264 |
| **Race** |  |  |  | 0.5083 |
| White | 554 (76.0%) | 509 (76.0%) | 45 (76.3%) |  |
| Black | 99 (13.6%) | 89 (13.3%) | 10 (16.9%) |  |
| Others | 76 (10.4%) | 72 (10.7%) | 4 (6.8%) |  |
| Unknown | 4 | 4 | 0 |  |
| **Marital status** |  |  |  | 0.1293 |
| Married | 386 (55.1%) | 358 (55.8%) | 28 (48.3%) |  |
| Single/Unmarried | 166 (23.7%) | 146 (22.7%) | 20 (34.5%) |  |
| Others | 148 (21.1%) | 138 (21.5%) | 10 (17.2%) |  |
| Unknown | 33 | 32 | 1 |  |
| **Family income** |  |  |  | 0.4243 |
| <$60,000 | 186 (25.4%) | 170 (25.2%) | 16 (27.1%) |  |
| $60,000-$74,999 | 293 (40.0%) | 274 (40.7%) | 19 (32.2%) |  |
| >$75,000 | 254 (34.7%) | 230 (34.1%) | 24 (40.7%) |  |
| **Grade** |  |  |  | 0.3253 |
| Low-grade | 181 (24.7%) | 171 (25.4%) | 10 (16.9%) |  |
| High-grade | 323 (44.1%) | 293 (43.5%) | 30 (50.8%) |  |
| Gx | 229 (31.2%) | 210 (31.2%) | 19 (32.2%) |  |
| **Tumor size (mm)** | 95.0 (60.0, 135.0) | 90.0 (60.0, 130.0) | 120.0 (76.2, 150.0) | 0.017\*5 |
| Unknown | 79 | 74 | 5 |  |
| **Histology** |  |  |  | 0.0913 |
| LMS | 448 (61.1%) | 418 (62.0%) | 30 (50.8%) |  |
| ESS | 285 (38.9%) | 256 (38.0%) | 29 (49.2%) |  |
| **T stage** |  |  |  | <0.001\*6 |
| T1 | 499 (68.1%) | 488 (72.4%) | 11 (18.6%) |  |
| T2 | 131 (17.9%) | 113 (16.8%) | 18 (30.5%) |  |
| T3 | 85 (11.6%) | 62 (9.2%) | 23 (39.0%) |  |
| T4 | 18 (2.5%) | 11 (1.6%) | 7 (11.9%) |  |
| **N stage** |  |  |  | <0.001\*6 |
| N0 | 680 (93.3%) | 637 (94.8%) | 43 (75.4%) |  |
| N1 | 49 (6.7%) | 35 (5.2%) | 14 (24.6%) |  |
| Unknown | 4 | 2 | 2 |  |
| **M stage** |  |  |  | 0.011\*3 |
| M0 | 628 (85.7%) | 584 (86.6%) | 44 (74.6%) |  |
| M1 | 105 (14.3%) | 90 (13.4%) | 15 (25.4%) |  |
| **FIGO stage** |  |  |  | <0.001\*3 |
| I | 442 (60.3%) | 433 (64.2%) | 9 (15.3%) |  |
| II | 82 (11.2%) | 74 (11.0%) | 8 (13.6%) |  |
| III | 89 (12.1%) | 68 (10.1%) | 21 (35.6%) |  |
| IV | 120 (16.4%) | 99 (14.7%) | 21 (35.6%) |  |
| **Surgery** |  |  |  | 0.031\*6 |
| TH+BSO | 629 (85.8%) | 582 (86.4%) | 47 (79.7%) |  |
| TH | 47 (6.4%) | 45 (6.7%) | 2 (3.4%) |  |
| RH/EH | 57 (7.8%) | 47 (7.0%) | 10 (16.9%) |  |
| **Pelvic lymph node dissection** |  |  |  | 0.6553 |
| No | 417 (59.7%) | 384 (59.9%) | 33 (56.9%) |  |
| Yes | 282 (40.3%) | 257 (40.1%) | 25 (43.1%) |  |
| Unknown | 34 | 33 | 1 |  |
| **Para-aortic lymph node dissection** |  |  |  | 0.9773 |
| No | 586 (84.1%) | 538 (84.1%) | 48 (84.2%) |  |
| Yes | 111 (15.9%) | 102 (15.9%) | 9 (15.8%) |  |
| Unknown | 36 | 34 | 2 |  |
| **Lymphadenectomy** |  |  |  | 0.5523 |
| No | 412 (58.9%) | 380 (59.2%) | 32 (55.2%) |  |
| Yes | 288 (41.1%) | 262 (40.8%) | 26 (44.8%) |  |
| Unknown | 33 | 32 | 1 |  |
| **Radiotherapy** |  |  |  | 0.3543 |
| No | 609 (83.9%) | 557 (83.5%) | 52 (88.1%) |  |
| Yes | 117 (16.1%) | 110 (16.5%) | 7 (11.9%) |  |
| Unknown | 7 | 7 | 0 |  |
| **Chemotherapy** |  |  |  | 0.033\*3 |
| No | 365 (53.8%) | 343 (55.0%) | 22 (40.0%) |  |
| Yes | 314 (46.2%) | 281 (45.0%) | 33 (60.0%) |  |
| Unknown | 54 | 50 | 4 |  |
| 1n (%); Mean (SD); Median (IQR) | | | | |
| 2\*p<0.05 | | | | |
| 3Pearson's Chi-squared test | | | | |
| 4Welch Two Sample t-test | | | | |
| 5Wilcoxon rank sum test | | | | |
| 6Fisher's exact test | | | | |